Table 2.
PTSD and depressive symptom severity at baseline and at endpoint according to CAPS and BDI scores: effectiveness analysis
| Outcome | Baseline Mean (SD) | Endpoint Mean (SD) | P | f |
|---|---|---|---|---|
| CAPS TOTAL | 0.49 | 0.46 | ||
| Topiramate (n = 17) | 78.76 (12.64) | 30.41 (30.90) | ||
| Placebo (n = 14) | 66.14 (22.63) | 35.78 (33.76) | ||
| Reexperiencing symptoms (CAPS‐B) | 0.64 | 0.21 | ||
| Topiramate (n = 17) | 23.05 (5.88) | 6.29 (9.07) | ||
| Placebo (n = 14) | 21.21 (7.15) | 9.28 (9.26) | ||
| Avoidance/numbing symptoms (CAPS‐C)* | 0.003 | 8.74 | ||
| Topiramate (n = 17) | 31.58 (7.13) | 12.17 (13.30) | ||
| Placebo (n = 14) | 24.78 (11.30) | 18.35 (17.54) | ||
| Hyperarousal symptoms (CAPS‐D) | 0.26 | 1.26 | ||
| Topiramate (n = 17) | 24.11 (5.69) | 11.29 (10.76) | ||
| Placebo (n = 14) | 20.14 (8.29) | 9 (9.42) | ||
| CGI | 0.71 | 0.13 | ||
| Topiramate (n = 17) | 4.82 (0.63) | 2.11 (1.69) | ||
| Placebo (n = 14) | 4.64 (0.74) | 2.71 (2.05) | ||
| BDI | 0.72 | 0.12 | ||
| Topiramate (n = 17) | 22.29 (9.47) | 13.81 (10.29) | ||
| Placebo (n = 14) | 22.0 (11.80) | 18.14 (14.77) | ||
*P < 0.05 statistically significant difference.
CAPS, Clinician‐Administered Posttraumatic Stress Scale; CGI, Clinical Global Impression; BDI, Beck Depression Inventory